Goldman Sachs Group Inc Neurocrine Biosciences Inc Transaction History

Goldman Sachs Group Inc

  • $580 Billion
  • Q2 2024

A detailed history of Goldman Sachs Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,132,589 shares of NBIX stock, worth $144 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,132,589
Previous 775,727 46.0%
Holding current value
$144 Million
Previous $107 Million 45.74%
% of portfolio
0.03%
Previous 0.02%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$130.86 - $143.19 $46.7 Million - $51.1 Million
356,862 Added 46.0%
1,132,589 $156 Million
Q1 2024

May 15, 2024
BUY
$130.4 - $143.74 $11 Million - $12.1 Million
84,095 Added 12.16%
775,727 $107 Million
Q4 2023

Feb 13, 2024
SELL
$106.07 - $132.76 $10.1 Million - $12.7 Million
-95,323 Reduced 12.11%
691,632 $91.1 Million
Q3 2023

May 14, 2024
BUY
$94.02 - $117.1 $8.96 Million - $11.2 Million
95,323 Added 13.78%
786,955 $88.5 Million
Q3 2023

Nov 14, 2023
SELL
$94.02 - $117.1 $3.54 Million - $4.41 Million
-37,682 Reduced 4.57%
786,955 $88.5 Million
Q2 2023

May 14, 2024
SELL
$89.53 - $104.87 $13 Million - $15.2 Million
-145,163 Reduced 14.97%
824,637 $77.8 Million
Q2 2023

Aug 14, 2023
SELL
$89.53 - $104.87 $13 Million - $15.2 Million
-145,163 Reduced 14.97%
824,637 $77.8 Million
Q1 2023

May 14, 2024
SELL
$94.11 - $123.02 $33.9 Million - $44.3 Million
-359,922 Reduced 27.07%
969,800 $98.2 Million
Q1 2023

May 11, 2023
SELL
$94.11 - $123.02 $33.9 Million - $44.3 Million
-359,922 Reduced 27.07%
969,800 $98.2 Million
Q4 2022

May 14, 2024
BUY
$106.72 - $127.06 $13.7 Million - $16.3 Million
127,932 Added 10.65%
1,329,722 $159 Million
Q4 2022

Feb 13, 2023
BUY
$106.72 - $127.06 $13.7 Million - $16.3 Million
127,932 Added 10.65%
1,329,722 $159 Million
Q3 2022

May 14, 2024
SELL
$92.03 - $107.81 $4.88 Million - $5.72 Million
-53,033 Reduced 4.23%
1,201,790 $128 Million
Q3 2022

Nov 10, 2022
SELL
$92.03 - $107.81 $4.88 Million - $5.72 Million
-53,033 Reduced 4.23%
1,201,790 $128 Million
Q2 2022

May 14, 2024
BUY
$75.79 - $100.07 $42.7 Million - $56.4 Million
563,191 Added 81.43%
1,254,823 $122 Million
Q2 2022

Aug 15, 2022
SELL
$75.79 - $100.07 $18.3 Million - $24.2 Million
-241,629 Reduced 16.15%
1,254,823 $122 Million
Q1 2022

May 16, 2022
SELL
$72.45 - $94.81 $2.03 Million - $2.66 Million
-28,063 Reduced 1.84%
1,496,452 $140 Million
Q4 2021

Feb 14, 2022
BUY
$79.65 - $106.22 $6.45 Million - $8.61 Million
81,017 Added 5.61%
1,524,515 $130 Million
Q3 2021

Nov 10, 2021
BUY
$86.18 - $99.03 $124 Million - $143 Million
1,443,498 New
1,443,498 $138 Million

Others Institutions Holding NBIX

# of Institutions
625
Shares Held
94.7M
Call Options Held
642K
Put Options Held
288K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email